文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-PSMA放射性配体治疗在未接受紫杉烷与已接受紫杉烷治疗的转移性去势抵抗性前列腺癌患者中的疗效结局:系统综述与荟萃分析

[177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis.
PubMed 文献 · J Nucl Med · 2023-05-11

该系统综述与荟萃分析纳入13篇文章共2068例转移性去势抵抗性前列腺癌患者,评估既往紫杉烷化疗对[177Lu]Lu-PSMA放射性配体治疗疗效的影响。未接受紫杉烷的患者生化缓解率、无进展生存期和总生存期均显著优于已接受紫杉烷的患者。作者认为需要进一步在未接受紫杉烷Setting中开展试验评估[177Lu]Lu-PSMA放射性配体治疗。

要点

  • 未接受紫杉烷患者[177Lu]Lu-PSMA治疗后生化缓解的汇总OR为1.82(95%CI 1.21-2.71)。
  • 未接受紫杉烷患者PSA缓解率为57.1%,已接受紫杉烷患者为39.5%,差值17.6%(95%CI 5.6%-28.9%)。
  • 未接受紫杉烷与更优的无进展生存期(汇总HR 0.60,95%CI 0.51-0.69)和总生存期(汇总HR 0.54,95%CI 0.43-0.68)相关。

核心结论

  • 未接受紫杉烷的转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA放射性配体治疗后的结局显著优于已接受紫杉烷治疗的患者。
  • 作者认为目前需要在未接受紫杉烷Setting中开展进一步试验评估[177Lu]Lu-PSMA放射性配体治疗。

研究设计与样本

  • 本系统综述与荟萃分析遵循PRISMA指南,检索PubMed、Scopus和Embase数据库,纳入截至2022年12月的文章。
  • 共纳入13篇文章,包含2068例患者。
  • 终点包括前列腺特异性抗原(PSA)缓解率、无进展生存期和总生存期;在可行时汇总个体患者数据。

主要发现

  • 在6篇文章(553例患者)中,未接受紫杉烷的患者[177Lu]Lu-PSMA放射性配体治疗后生化缓解的几率显著更优(汇总OR 1.82,95%CI 1.21-2.71)。
  • 3篇文章的个体患者数据荟萃分析显示,未接受紫杉烷患者PSA缓解率显著高于已接受紫杉烷患者(57.1% vs 39.5%;差值17.6%,95%CI 5.6%-28.9%)。
  • 未接受紫杉烷状态也是[177Lu]Lu-PSMA放射性配体治疗后无进展生存期显著更优的预测因素(5篇文章;1027例患者;汇总HR 0.60,95%CI 0.51-0.69)。
  • 未接受紫杉烷状态也是[177Lu]Lu-PSMA放射性配体治疗后总生存期显著更优的预测因素(8篇文章;1594例患者;汇总HR 0.54,95%CI 0.43-0.68)。
  • 未发现发表偏倚证据。

关键数值与推荐

  • 未接受紫杉烷患者生化缓解的汇总OR为1.82(95%CI 1.21-2.71),显著优于已接受紫杉烷患者。
  • 未接受紫杉烷患者PSA缓解率57.1%,已接受紫杉烷患者39.5%,差值17.6%(95%CI 5.6%-28.9%)。
  • 未接受紫杉烷患者无进展生存期汇总HR为0.60(95%CI 0.51-0.69)。
  • 未接受紫杉烷患者总生存期汇总HR为0.54(95%CI 0.43-0.68)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为目前需要在未接受紫杉烷Setting中开展进一步试验评估[177Lu]Lu-PSMA放射性配体治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA) inhibitors ([177Lu]Lu-PSMA) is currently approved for patients with metastatic castration-resistant prostate cancer (mCRPC) after progression with at least 1 taxane and 1 androgen-receptor-pathway inhibitor. However, the impact of prior chemotherapy on [177Lu]Lu-PSMA-RLT outcomes is debatable, with various studies showing inconsistent results. This study was conducted to precisely evaluate the impact of prior taxane chemotherapy on response and survival outcomes in mCRPC patients after [177Lu]Lu-PSMA-RLT. Methods: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Searches in PubMed, Scopus, and Embase were made using relevant key words, and articles up to December 2022 were included. The endpoints included prostate-specific antigen (PSA) response rate (RR), progression-free survival, and overall survival (OS). Individual patient data were pooled when feasible. Univariate odds ratios (ORs) and hazard ratios (HRs) were extracted from the individual articles, and pooled estimates and 95% CIs were generated using metaanalysis. Results: Thirteen articles comprising 2,068 patients were included. In 6 articles (553 patients), taxane-naïve patients had significantly better odds of biochemical response after [177Lu]Lu-PSMA-RLT (pooled OR, 1.82; 95% CI, 1.21-2.71). Individual patient data metaanalysis for PSA RRs in 3 articles revealed a significantly higher PSA RR in the taxane-naïve versus taxane-treated patients (57.1% vs. 39.5%; difference, 17.6%; 95% CI, 5.6%-28.9%). Further, taxane-naïve status was also a predictor of significantly better progression-free survival (5 articles; 1,027 patients; pooled HR, 0.60; 95% CI, 0.51-0.69) and OS (8 articles; 1,594 patients; pooled HR, 0.54; 95% CI, 0.43-0.68) after [177Lu]Lu-PSMA-RLT. There was no evidence of publication bias. Conclusion: mCRPC patients with no prior taxanes had significantly better outcomes after [177Lu]Lu-PSMA-RLT than did taxane-treated patients. Further trials evaluating [177Lu]Lu-PSMA-RLT in the taxane-naïve setting are now required.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Satapathy S, Sahoo RK, Bal C, et al. [177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis. J Nucl Med. 2023. PMID: 37169534. doi:10.2967/jnumed.123.265414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。